2025
Significance of Coronary Artery Calcifications and Ischemic Electrocardiographic Changes Among Patients Undergoing Myocardial Perfusion Imaging
Kokkinidis D, Kyriakoulis I, Chui P, Agarwal R, Liu Y, Khera R, Sinusas A, Velazquez E, Miller E, Feher A. Significance of Coronary Artery Calcifications and Ischemic Electrocardiographic Changes Among Patients Undergoing Myocardial Perfusion Imaging. JACC Advances 2025, 4: 101618. PMID: 39983619, PMCID: PMC11891677, DOI: 10.1016/j.jacadv.2025.101618.Peer-Reviewed Original ResearchCoronary artery calcificationMyocardial perfusion imagingIschemic ECG changesLow event ratesECG changesNormal perfusionArtery calcificationPerfusion imagingSingle-photon emission computed tomography/computed tomographyStress ECGCAC evaluationPresence of coronary artery calcificationSuspected coronary artery diseaseMedian follow-upEvent ratesIschemic electrocardiographic changesAnalysis to patientsComposite endpoint rateCoronary artery diseaseTomography/computed tomographyPrognostic informationMACE rateFollow-upSubgroup analysisAdverse outcomes
2024
Vigorous Exercise in Patients With Congenital Long QT Syndrome: Results of the Prospective, Observational, Multinational LIVE-LQTS Study
Lampert R, Day S, Ainsworth B, Burg M, Marino B, Salberg L, Tome Esteban M, Abrams D, Aziz P, Barth C, Behr E, Bell C, Berul C, Bos J, Bradley D, Cannom D, Cannon B, Concannon M, Cerrone M, Czosek R, Dubin A, Dziura J, Erickson C, Estes N, Etheridge S, Goldenberg I, Gray B, Haglund-Turnquist C, Harmon K, James C, Johnsrude C, Kannankeril P, Lara A, Law I, Li F, Link M, Molossi S, Olshansky B, Noseworthy P, Saarel E, Sanatani S, Shah M, Simone L, Skinner J, Tomaselli G, Ware J, Webster G, Zareba W, Zipes D, Ackerman M. Vigorous Exercise in Patients With Congenital Long QT Syndrome: Results of the Prospective, Observational, Multinational LIVE-LQTS Study. Circulation 2024, 150: 516-530. PMID: 39051104, DOI: 10.1161/circulationaha.123.067590.Peer-Reviewed Original ResearchConceptsVigorous exerciseLong QT syndromeGenotyped long QT syndromeCongenital long QT syndromeClinical events committeeComposite end pointHazard ratioNational Death Index searchCompetitive sports participationQT syndromeDecision-making discussionsEvents committeeVentricular arrhythmiasFollow-upEvent ratesBlinded clinical events committeeMetabolic equivalentsPhysical activityExercise groupEnd pointsRisk of ventricular arrhythmiasMultivariate Cox regression analysisSudden cardiac arrestSports participationCardiac event rateAssessment of Days Alive Out of Hospital as a Possible End Point in Trials of Stroke Prevention for Atrial Fibrillation: A ROCKET AF Analysis
Harrington J, Hellkamp A, Mahaffey K, Breithardt G, Halperin J, Hankey G, Becker R, Nessel C, Berkowitz S, Fox K, Singer D, Goodman S, Patel M, Piccini J. Assessment of Days Alive Out of Hospital as a Possible End Point in Trials of Stroke Prevention for Atrial Fibrillation: A ROCKET AF Analysis. Journal Of The American Heart Association 2024, 13: e028951. PMID: 38780169, PMCID: PMC11255646, DOI: 10.1161/jaha.122.028951.Peer-Reviewed Original ResearchAtrial fibrillationROCKET AFClinical trialsEnd pointsLow overall event ratesInternational double-blindClinical trials of interventionsRandomized clinical trialsAssessment of dayOverall event rateDouble-blindAnticoagulation trialsTreatment armsIncreased riskWarfarinTrials of interventionsClinical utilityTreatment groupsEvent ratesPatientsDAOHPoisson regressionComorbiditiesFibrillationTrialsIntermediate and long-term residual cardiovascular risk in patients with established cardiovascular disease treated with statins
Vijayaraghavan K, Baum S, Desai N, Voyce S. Intermediate and long-term residual cardiovascular risk in patients with established cardiovascular disease treated with statins. Frontiers In Cardiovascular Medicine 2024, 10: 1308173. PMID: 38288054, PMCID: PMC10822878, DOI: 10.3389/fcvm.2023.1308173.Peer-Reviewed Original ResearchLDL-CCV riskPeripheral arterial diseaseArtery diseaseCumulative incidence of CV eventsCV diseaseLowering of low-density lipoprotein cholesterolPatients treated with statinsIncidence of CV eventsLong-term event ratesWell-controlled LDL-CLow-density lipoprotein cholesterolLDL-C reductionAdd-on agentEvent ratesFirst-line treatmentResidual cardiovascular riskCV event ratesCoronary artery diseaseCV-related deathOmega-3 fatty acids eicosapentaenoic acidFirst-lineCumulative incidenceEicosapentaenoic acidCV eventsReal‐world analysis of adverse event rates after initiation of ibrutinib among Medicare beneficiaries with chronic lymphocytic leukemia
Huntington S, de Nigris E, Puckett J, Kamal‐Bahl S, Farooqui M, Ryland K, Sarpong E, Leng S, Yang X, Doshi J. Real‐world analysis of adverse event rates after initiation of ibrutinib among Medicare beneficiaries with chronic lymphocytic leukemia. Cancer Medicine 2024, 13: e6953. PMID: 38348963, PMCID: PMC10832339, DOI: 10.1002/cam4.6953.Peer-Reviewed Original ResearchConceptsChronic lymphocytic leukemiaRate of adverse eventsIncidence rate of adverse eventsAdverse eventsPatient-monthsLymphocytic leukemiaIncidence ratePatients treated with ibrutinibTreatment of chronic lymphocytic leukemiaStandard-of-care therapyNon-discontinuationInitiation of ibrutinibBTK inhibitor ibrutinibAdverse event ratesPotential side effectsInhibitor ibrutinibMedicare beneficiariesReal-world analysisAtrial fibrillationFollow-upIbrutinibSide effectsReal-world outcomesEvent ratesLeukemia
2023
Radiotherapy Plus Cisplatin With or Without Lapatinib for Non–Human Papillomavirus Head and Neck Carcinoma
Wong S, Torres-Saavedra P, Saba N, Shenouda G, Bumpous J, Wallace R, Chung C, El-Naggar A, Gwede C, Burtness B, Tennant P, Dunlap N, Redman R, Stokes W, Rudra S, Mell L, Sacco A, Spencer S, Nabell L, Yao M, Cury F, Mitchell D, Jones C, Firat S, Contessa J, Galloway T, Currey A, Harris J, Curran W, Le Q. Radiotherapy Plus Cisplatin With or Without Lapatinib for Non–Human Papillomavirus Head and Neck Carcinoma. JAMA Oncology 2023, 9: 1565-1573. PMID: 37768670, PMCID: PMC10540060, DOI: 10.1001/jamaoncol.2023.3809.Peer-Reviewed Original ResearchConceptsProgression-free survivalAdverse event ratesOverall survivalStage IIIClinical trialsAcute adverse event ratesProgression-free survival ratesEnd pointEvent ratesAnti-epidermal growth factor receptor (EGFR) antibodiesBenefit of chemoradiotherapyZubrod performance statusPrimary end pointSecondary end pointsCycles of cisplatinAddition of lapatinibEGFR antibody therapyGrowth factor receptor antibodyLog-rank testDual EGFRPlus CisplatinFrontline therapyPerformance statusAntibody therapyNeck carcinomaIntracardiac vs Transesophageal Echocardiography for Left Atrial Appendage Occlusion With Watchman FLX in the U.S.
Ferro E, Alkhouli M, Nair D, Kapadia S, Hsu J, Gibson D, Freeman J, Price M, Roy K, Allocco D, Yeh R, Piccini J. Intracardiac vs Transesophageal Echocardiography for Left Atrial Appendage Occlusion With Watchman FLX in the U.S. JACC Clinical Electrophysiology 2023, 9: 2587-2599. PMID: 37831030, DOI: 10.1016/j.jacep.2023.08.004.Peer-Reviewed Original ResearchConceptsAtrial appendage occlusionTransesophageal echocardiographyIntracardiac echocardiographyBaseline characteristicsAppendage occlusionLeft atrial appendage occlusionPericardial effusion rateSuccessful device implantationAdverse event ratesSimilar baseline characteristicsUnadjusted mortality ratesHigh rateICE patientsTEE patientsPericardial effusionPivotal trialsDevice implantationGeneral anesthesiaAdjusted comparisonsProcedural timeLAAO devicesDevice deliveryMortality rateEvent ratesEchocardiographyImpact of COVID‐19 in patients with heart failure with mildly reduced or preserved ejection fraction enrolled in the DELIVER trial
Bhatt A, Kosiborod M, Claggett B, Miao Z, Vaduganathan M, Lam C, Hernandez A, Martinez F, Inzucchi S, Shah S, de Boer R, Jhund P, Desai A, Fang J, Han Y, Comin‐Colet J, Drożdż J, Vardeny O, Merkely B, Lindholm D, Peterson M, Langkilde A, McMurray J, Solomon S. Impact of COVID‐19 in patients with heart failure with mildly reduced or preserved ejection fraction enrolled in the DELIVER trial. European Journal Of Heart Failure 2023, 25: 2177-2188. PMID: 37771274, DOI: 10.1002/ejhf.3043.Peer-Reviewed Original ResearchCOVID-19 diagnosisRisk of deathHeart failureEjection fractionPandemic onsetTrial participantsCOVID-19Death rateMajor hypoglycaemic eventsChronic heart failureTime of diagnosisCOVID-19 survivorsDiabetic ketoacidosisHypoglycaemic eventsClinical outcomesHF eventsCOVID-19 casesTreatment benefitClinical riskCardiovascular trialsDeath/DapagliflozinEvent ratesPatientsDiagnosisEV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma☆
Rosenberg J, Powles T, Sonpavde G, Loriot Y, Duran I, Lee J, Matsubara N, Vulsteke C, Castellano D, Mamtani R, Wu C, Matsangou M, Campbell M, Petrylak D. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma☆. Annals Of Oncology 2023, 34: 1047-1054. PMID: 37678672, DOI: 10.1016/j.annonc.2023.08.016.Peer-Reviewed Original ResearchConceptsProgression-free survivalEnfortumab vedotinAdverse eventsUrothelial carcinomaTreatment-related adverse event ratesMeaningful overall survival benefitPrior platinum-containing chemotherapyWhite blood cell countEvent ratesAdvanced urothelial carcinomaMetastatic urothelial carcinomaOverall survival benefitPeripheral sensory neuropathyPlatinum-containing chemotherapyNew safety signalsPhase III trialsAdverse event ratesRisk of deathBlood cell countIII trialsMaculopapular rashNeutrophil countObjective responseOverall survivalSurvival benefitEfficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure
Kondo T, Wang X, Yang M, Jhund P, Claggett B, Vaduganathan M, Hernandez A, Lam C, Inzucchi S, Martinez F, de Boer R, Kosiborod M, Desai A, Køber L, Ponikowski P, Sabatine M, Langkilde A, Petersson M, Zaozerska N, Bachus E, Solomon S, McMurray J. Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure. Journal Of The American College Of Cardiology 2023, 82: 1014-1026. PMID: 37610398, DOI: 10.1016/j.jacc.2023.05.056.Peer-Reviewed Original ResearchConceptsSafety of dapagliflozinHeart failurePrimary outcomeEjection fractionPatient-level pooled analysisBenefit of dapagliflozinEfficacy of dapagliflozinReduced ejection fractionEffect of dapagliflozinDAPA-HFCardiovascular deathClinical characteristicsDiscontinuation ratesPatient characteristicsPooled analysisDapagliflozinPatientsBackground treatmentEvent ratesInhibitor efficacyEfficacyGeographic regionsOutcomesTreatmentPrevious reports
2022
Trends in Adverse Event Rates in Hospitalized Patients, 2010-2019
Eldridge N, Wang Y, Metersky M, Eckenrode S, Mathew J, Sonnenfeld N, Perdue-Puli J, Hunt D, Brady PJ, McGann P, Grace E, Rodrick D, Drye E, Krumholz HM. Trends in Adverse Event Rates in Hospitalized Patients, 2010-2019. JAMA 2022, 328: 173-183. PMID: 35819424, PMCID: PMC9277501, DOI: 10.1001/jama.2022.9600.Peer-Reviewed Original ResearchMeSH KeywordsAccidental FallsAdultAgedAged, 80 and overCross InfectionCross-Sectional StudiesDrug-Related Side Effects and Adverse ReactionsFemaleHeart FailureHospitalizationHumansMaleMedicareMiddle AgedMyocardial InfarctionPatient SafetyPneumoniaPostoperative ComplicationsPressure UlcerRisk AssessmentSurgical Procedures, OperativeUnited StatesConceptsMajor surgical proceduresAcute myocardial infarctionAdverse event ratesGeneral adverse eventsAdverse eventsHeart failureAdverse drug eventsAcute care hospitalsMyocardial infarctionHospital-acquired infectionsSurgical proceduresEvent ratesHospital dischargeCare hospitalDrug eventsMedicare Patient Safety Monitoring SystemSerial cross-sectional studyPatient safetyUS acute care hospitalsHospital adverse eventsSignificant decreaseSurgical procedure groupsCross-sectional studyRisk-adjusted ratesAdult patientsDeucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial
Armstrong A, Gooderham M, Warren R, Papp K, Strober B, Thaçi D, Morita A, Szepietowski J, Imafuku S, Colston E, Throup J, Kundu S, Schoenfeld S, Linaberry M, Banerjee S, Blauvelt A. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. Journal Of The American Academy Of Dermatology 2022, 88: 29-39. PMID: 35820547, DOI: 10.1016/j.jaad.2022.07.002.Peer-Reviewed Original ResearchConceptsSevere plaque psoriasisGlobal assessment scorePlaque psoriasisWeek 16Static Physician's Global Assessment scoreResponse ratePhysician Global Assessment scoreCoprimary end pointsAdverse event ratesOne-year durationPASI 75Psoriasis AreaWeek 52Psoriasis treatmentPlaceboSafety resultsDeucravacitinibApremilastEnd pointEvent ratesAssessment scoresPsoriasisSeverity IndexKinase 2 inhibitorTyrosine kinase 2 inhibitorSelf-Reported COVID-19 Infections and Social Mixing Behavior at Oncology Meetings
Talcott WJ, Chen K, Peters GW, Reddy KK, Weintraub SM, Mougalian SS, Adelson K, Evans SB. Self-Reported COVID-19 Infections and Social Mixing Behavior at Oncology Meetings. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: 30-38. PMID: 35598798, PMCID: PMC9119957, DOI: 10.1016/j.ijrobp.2022.05.002.Peer-Reviewed Original ResearchConceptsSelf-reported COVID-19 infectionCOVID-19 infectionOncology meetingsEra of vaccinationCOVID-19 positivityCOVID-19 positivity ratesOncology annual meetingsPerson attendeesAmerican SocietyCOVID-19Risk of diseasePerson meetingsPositivity rateNew COVID-19 infectionsResponse rateEvent ratesSocial distancing mandatesNatural history of bicuspid aortic valves and ascending aortic aneurysms: Aortic center experience
Bellaire CP, Tharakan SM, Roy J, Puskas JD, Di Luozzo G. Natural history of bicuspid aortic valves and ascending aortic aneurysms: Aortic center experience. Journal Of Cardiac Surgery 2022, 37: 2326-2335. PMID: 35535018, DOI: 10.1111/jocs.16597.Peer-Reviewed Original ResearchConceptsBicuspid aortic valveAdverse event ratesTAV patientsEntire cohortAortic aneurysmAortic valveComputerized tomographyLow adverse event ratesOverall adverse event rateNatural historyEvent ratesTricuspid aortic valve patientsValve typeRoutine computerized tomographyMore CT scansAortic valve patientsCoronary artery diseaseMean aneurysm sizeAneurysm growth rateAortic valve typeSimilar natural historyAortic eventsConservative managementSmoking historyUnmatched cohortPhase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
Lim M, Weller M, Idbaih A, Steinbach J, Finocchiaro G, Raval RR, Ansstas G, Baehring J, Taylor JW, Honnorat J, Petrecca K, De Vos F, Wick A, Sumrall A, Sahebjam S, Mellinghoff IK, Kinoshita M, Roberts M, Slepetis R, Warad D, Leung D, Lee M, Reardon DA, Omuro A. Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. Neuro-Oncology 2022, 24: 1935-1949. PMID: 35511454, PMCID: PMC9629431, DOI: 10.1093/neuonc/noac116.Peer-Reviewed Original ResearchConceptsProgression-free survivalOverall survivalMGMT promoterBaseline corticosteroidsTreatment-related adverse event ratesImmune checkpoint inhibitor nivolumabNew safety signalsPhase III trialsAdverse event ratesCheckpoint inhibitor nivolumabCare radiotherapyInhibitor nivolumabPrimary endpointIII trialsSame regimenExperience recurrenceNivolumabSafety signalsPlaceboPatientsRadiotherapyTemozolomideEvent ratesMonthsPhase III
2021
Thromboembolic events following cardioversion of acute atrial fibrillation and flutter: a systematic review and meta-analysis
Wong BM, Perry JJ, Cheng W, Zheng B, Guo K, Taljaard M, Skanes AC, Stiell IG. Thromboembolic events following cardioversion of acute atrial fibrillation and flutter: a systematic review and meta-analysis. Canadian Journal Of Emergency Medicine 2021, 23: 500-511. PMID: 33715143, DOI: 10.1007/s43678-021-00103-0.Peer-Reviewed Original ResearchConceptsOral anticoagulation useAcute atrial fibrillationAnticoagulation useThromboembolic eventsAtrial fibrillationThromboembolic riskFlutter patientsInsufficient evidencePrimary analysisSecondary analysisDerSimonian-Laird random-effects modelSafety of cardioversionPrognostic Studies toolRisk of biasRandom-effects modelBackgroundRecent studiesInclusion criteriaMAIN OUTCOMELower riskFibrillationSystematic reviewEvent ratesCardioversionMore studiesPatients
2020
Can the Absence of Hypertension Refine the Risk Assessment of Older Adults for Future Cardiovascular Events?
Nanna MG, Navar AM, Wojdyla D, Nelson AJ, Sullivan AE, Peterson ED. Can the Absence of Hypertension Refine the Risk Assessment of Older Adults for Future Cardiovascular Events? The American Journal Of Cardiology 2020, 142: 83-90. PMID: 33279483, PMCID: PMC8221431, DOI: 10.1016/j.amjcard.2020.11.027.Peer-Reviewed Original ResearchConceptsSystolic blood pressureAtherosclerotic cardiovascular diseaseAbsence of hypertensionBlood pressureCardiovascular diseaseCardiovascular eventsEvent ratesOlder adultsLower CVD event ratesLower systolic blood pressureASCVD event ratesCVD event ratesDiastolic blood pressureFuture cardiovascular eventsASCVD riskRisk stratificationPooled cohortMultivariable modelingHypertensionRisk scoreLower riskRisk estimatesNational InstituteObserved event ratesAdultsThe New Trainee Effect in Tracheal Intubation Procedural Safety Across PICUs in North America: A Report From National Emergency Airway Registry for Children.
Branca A, Tellez D, Berkenbosch J, Rehder KJ, Giuliano JS, Gradidge E, Shults J, Turner DA, Nett S, Krawiec C, Edwards LR, Pinto M, Harwayne-Gidansky I, Bysani GK, Shenoi A, Breuer RK, Toedt-Pingel I, Parsons SJ, Orioles A, Al-Subu A, Konyk L, Panisello J, Adu-Darko M, Tarquinio K, François T, Emeriaud G, Lee A, Meyer K, Glater-Welt LB, Polikoff L, Kelly SP, Tallent S, Napolitano N, Nadkarni V, Nishisaki A. The New Trainee Effect in Tracheal Intubation Procedural Safety Across PICUs in North America: A Report From National Emergency Airway Registry for Children. Pediatric Critical Care Medicine 2020, 21: 1042-1050. PMID: 32740182, DOI: 10.1097/pcc.0000000000002480.Peer-Reviewed Original ResearchConceptsFirst-attempt successCritical care medicine fellowsNational Emergency Airway RegistryTracheal intubationAttempt successAirway RegistryPediatric critical care medicine fellowship programsPediatric critical care medicine fellowsPediatric critical care medicine fellowshipCritical care medicine fellowshipEvent ratesAdverse tracheal intubationNorth American PICUsRetrospective cohort studyCritical care medicine fellowship programsYear of fellowshipIntubation safetyAdverse eventsCohort studyProcedural safetyIntubationSafety outcomesHigh riskPICUsClinical fellowshipA Randomized Trial of a Multifactorial Strategy to Prevent Serious Fall Injuries
Bhasin S, Gill TM, Reuben DB, Latham NK, Ganz DA, Greene EJ, Dziura J, Basaria S, Gurwitz JH, Dykes PC, McMahon S, Storer TW, Gazarian P, Miller ME, Travison TG, Esserman D, Carnie MB, Goehring L, Fagan M, Greenspan SL, Alexander N, Wiggins J, Ko F, Siu AL, Volpi E, Wu AW, Rich J, Waring SC, Wallace RB, Casteel C, Resnick NM, Magaziner J, Charpentier P, Lu C, Araujo K, Rajeevan H, Meng C, Allore H, Brawley BF, Eder R, McGloin JM, Skokos EA, Duncan PW, Baker D, Boult C, Correa-de-Araujo R, Peduzzi P. A Randomized Trial of a Multifactorial Strategy to Prevent Serious Fall Injuries. New England Journal Of Medicine 2020, 383: 129-140. PMID: 32640131, PMCID: PMC7421468, DOI: 10.1056/nejmoa2002183.Peer-Reviewed Original ResearchConceptsSerious fall injuriesFall injuriesIntervention groupControl groupUsual careMultifactorial interventionRate of hospitalizationPrimary care practicesCluster-randomized trialCommunity-dwelling adultsFirst-event analysisYears of ageHealth care systemRate of fallElectronic health recordsBaseline characteristicsPrimary outcomeRandomized trialsMean ageEfficacy trialsIndividualized planCare practicesInjuryMultifactorial strategyEvent ratesRates and Predictors of Patient Underreporting of Hospitalizations During Follow-Up After Acute Myocardial Infarction
Caraballo C, Khera R, Jones PG, Decker C, Schulz W, Spertus JA, Krumholz HM. Rates and Predictors of Patient Underreporting of Hospitalizations During Follow-Up After Acute Myocardial Infarction. Circulation Cardiovascular Quality And Outcomes 2020, 13: e006231. PMID: 32552061, PMCID: PMC9465954, DOI: 10.1161/circoutcomes.119.006231.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionMyocardial infarctionHospitalization eventsMedical recordsLongitudinal multicenter cohort studyMulticenter cohort studyMedical record abstractionDifferent patient characteristicsHealth care eventsPatients' underreportingTRIUMPH registryAccuracy of reportingCohort studyPatient characteristicsRecord abstractionProspective studyClinical studiesClinical investigationHospitalizationPatientsCare eventsInfarctionEvent ratesParticipantsPredictors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply